Researchers are testing a slew of targeted therapeutic strategies in lung cancer. Signs are emerging that these therapies are gaining increasing traction in what has long been one of oncology's minefields. Malorye Allison investigates.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Chustecka, Z. Medscape Today, 7 June 2010 <http://www.medscape.com/viewarticle/723075>
Stinchcombe, T.E. & Govindan, R. Lancet Oncol. 11, 604–605 (2010).
Subramanian, J. et al. J. Thorac. Oncol. 5, 1116–1119 (2010).
AstraZeneca. IRESSA Label Change Press Release (AstraZeneca, London) http://www.iressa-us.com/news.asp (17 June 2005).
Polverino, A. et al. Cancer Res. 66, 8715–8721 (2006).
Bass, M.B. et al. J. Clin. Oncol. 28, 15s, Suppl; abstr 3037 (2010).
Zhang, X. et al. J. Nucl. Med. 47, 113–121 (2006).
Gambhir, S.S. et al. PLoS Med. 5, 1287–1297 (2008).
Pao, W. et al. PLoS Med. 2, e73 (2005).
Allison, M. Nat. Biotechnol. 28, 383–384 (2010).
Lawson, M.H. et al. J. Thorac. Oncol. 5, 956–963 (2010).
Kornblau, S.M. et al. Clin. Cancer Res. 16, 3721–3733 (2010).
Rosen, D.B. et al. PLoS ONE 5, e12405 (2010).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Allison, M. Turning the tide in lung cancer. Nat Biotechnol 28, 999–1002 (2010). https://doi.org/10.1038/nbt1010-999
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1010-999
